Protocols of Belonging
A decision about a peptide protocol rarely begins in a clinic. It begins in a search bar, a group chat, ...
The Parallel Care Pathway
A decision about a peptide protocol rarely begins in a clinic. It begins in a search bar, a group chat, ...
Optimization or Overreach
A decision about a peptide protocol rarely begins in a clinic. It begins in a search bar, a group chat, ...
Between Annual Checkups and Weekly Biomarkers
A decision about a peptide protocol rarely begins in a clinic. It begins in a search bar, a group chat, ...
Exit Multiples and Clinical Evidence
Regulation rarely moves at the speed of capital formation. The proliferation of privately financed peptide clinics illustrates a recurring structural ...
The Subscription Clinic Economy
The waiting room has begun to resemble a product funnel. The growth of subscription-based peptide clinics signals a deeper transformation ...
When Capital Meets Molecules
Capital rarely waits for clinical consensus. The rapid expansion of direct‑to‑consumer peptide clinics reflects a deeper convergence of investor time ...
Earnings Calls, Appetite Signals, and the Future of Benefits
The quarterly earnings call turned unexpectedly clinical. Analysts asked about weight loss drugs. Employers responding to GLP‑1 adoption pressures increasingly ...
The Workforce Becomes a Metabolic Portfolio
The quiet revolution began in the cafeteria. Employers analyzing aggregate nutrition data alongside GLP‑1 prescription trends are discovering that pharmacologic ...
Metabolic Risk as Corporate Strategy
The spreadsheet was supposed to be about premiums. Instead, it became a referendum on metabolism. Across boardrooms and benefits committees, ...
The Governance Problem Hidden Inside a Weight Loss Drug
Innovation often arrives disguised as inevitability. Retatrutide’s trajectory through clinical trials, investor speculation, and policy discourse suggests a future in ...
The Politics of Therapeutic Legitimacy
Medicine prefers to imagine itself as insulated from politics. Reality is less accommodating. The recent association of peptide deregulation discourse ...
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more